sorafenib has been researched along with h 89 in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (h 89) | Trials (h 89) | Recent Studies (post-2010) (h 89) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 1,619 | 0 | 409 |
Protein | Taxonomy | sorafenib (IC50) | h 89 (IC50) |
---|---|---|---|
Rho-associated protein kinase 2 | Homo sapiens (human) | 1.9504 | |
Ribosomal protein S6 kinase alpha-5 | Homo sapiens (human) | 0.12 | |
cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) | 0.073 | |
cAMP-dependent protein kinase catalytic subunit alpha | Mus musculus (house mouse) | 0.381 | |
cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | 0.6365 | |
cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | 0.6365 | |
cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | 0.6365 | |
Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | 0.08 | |
RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | 1.9886 | |
RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | 0.5417 | |
Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | 0.27 | |
RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | 0.3207 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
Danhier, P; Gallez, B; Gregoire, V; Jordan, BF; Magat, J; Masquelier, J; Mignion, L; Muccioli, GG; Porporato, PE; Sonveaux, P | 1 |
Chen, X; Cui, L; Feng, S; Guo, X; Li, B; Ning, G; Wang, T; Wang, X; Wang, Z; Xia, Z; Yu, M; Yuan, W; Yuan, X; Zhang, L; Zhang, Y; Zhang, Z | 1 |
3 other study(ies) available for sorafenib and h 89
Article | Year |
---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Topics: Animals; Antineoplastic Agents; Choline Kinase; Diffusion Magnetic Resonance Imaging; Female; Heterografts; Humans; Isoquinolines; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protons; Sorafenib; Sulfonamides | 2016 |
Sorafenib promotes sensory conduction function recovery via miR-142-3p/AC9/cAMP axis post dorsal column injury.
Topics: Adenylyl Cyclases; Animals; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Female; GAP-43 Protein; Guanosine Triphosphate; Interleukin-6; Isoquinolines; MicroRNAs; Phosphorylation; Rats; Recovery of Function; Rhodamines; RNA, Small Interfering; Sciatic Nerve; Sensation; Signal Transduction; Sorafenib; Spinal Cord Injuries; Sulfonamides; Tyrphostins; Up-Regulation | 2019 |